Global Leading Market Research Publisher Global Info Research announces the release of its latest report *”Anti-CD31 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*.
Angiogenesis researchers, vascular biologists, and oncology pathologists face a critical analytical requirement: specific detection of CD31 (PECAM-1, platelet endothelial cell adhesion molecule-1) — the gold standard endothelial cell marker for quantifying microvascular density (MVD), visualizing blood vessel formation, and studying endothelial cell-cell interactions in tumor angiogenesis, wound healing, and cardiovascular research. Anti-CD31 antibody directly addresses this need. CD31 is a 130 kDa transmembrane glycoprotein expressed constitutively on endothelial cells (continuous, fenestrated, and sinusoidal), platelets, and some leukocyte subsets (macrophages, neutrophils). Its strong, continuous membrane staining pattern in tissue sections makes it the preferred marker for quantifying tumor angiogenesis (microvessel density, MVD) and evaluating anti-angiogenic therapies. Anti-CD31 antibodies are available in monoclonal (high specificity, batch consistency) and polyclonal formats, with applications in immunohistochemistry (IHC) for tissue MVD, immunofluorescence (IF) for vascular co-localization, Western blot, immunoprecipitation, and flow cytometry for endothelial cell analysis. This deep-dive analysis evaluates market dynamics, monoclonal vs. polyclonal segmentation, and adoption across oncology, vascular biology, and regenerative medicine applications.
The global market for anti-CD31 antibody was estimated to be worth US52millionin2025andisprojectedtoreachUS52millionin2025andisprojectedtoreachUS 76 million by 2032, growing at a CAGR of 5.6% from 2026 to 2032. Growth is driven by increasing angiogenesis research funding (solid tumor vasculature,anti-VEGF resistance mechanisms), demand for validated IHC antibodies for clinical trial pharmacodynamic (PD) biomarkers (anti-angiogenic agents), and expansion of endothelial biology research in organoid vascularization and regenerative medicine.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5985683/anti-cd31-antibody
1. Core Technical Applications and MVD Quantification
Anti-CD31 antibodies serve as the primary endothelial cell marker across multiple platforms:
| Application | Primary Use | Key Clone | Critical Quality Parameter | Typical Format |
|---|---|---|---|---|
| Immunohistochemistry (IHC) | Tumor microvessel density (MVD) quantification, angiogenesis assessment | JC70A (mouse), 1A10 (mouse) | Strong continuous membrane staining, low background (no stromal/immune cell staining), validated on FFPE | HRP/DAB with polymer detection |
| Immunofluorescence (IF) | Vascular co-localization (α-SMA, NG2, VE-cadherin) | JC70A, MEC 13.3 (mouse) | Bright signal, negligible endothelial autofluorescence, compatibility with permeability dyes | Alexa Fluor (488, 555, 647) conjugates |
| Western Blot (WB) | CD31 expression (130 kDa) | JC70A, 5.6E, MEC 13.3 | Single specific band at 130 kDa, detection of denatured protein, no non-specific bands | HRP-conjugated or primary + anti-mouse/rabbit HRP |
| Flow Cytometry (Surface) | Endothelial cell identification (lung, heart, tumor) | MEC 13.3 (mouse), 390 (human) | Bright fluorophore (FITC, PE, APC), minimal nonspecific binding to non-endothelial cells | FITC, PE, APC conjugates |
独家观察 (Exclusive Insight): While most market analysis focuses on human CD31 antibodies, the fastest-growing segment since Q4 2025 is mouse-specific CD31 antibodies (clone MEC 13.3) for preclinical syngeneic tumor models and orthotopic xenografts. Anti-angiogenic drug development (VEGF/R inhibitors, angiopoietin-2 inhibitors, TIE-2 agonists) increasingly relies on mouse tumor models (4T1 breast, MC38 colon, B16 melanoma) to assess microvessel density changes pre/post-treatment. A January 2026 review of preclinical literature found that 68% of anti-angiogenic efficacy studies used clone MEC 13.3 for CD31 IHC, up from 52% in 2020. Clone MEC 13.3 (rat anti-mouse) has superior membrane staining quality in frozen sections compared to cross-reactive human antibodies, with lower background in mouse tissue. Rat anti-mouse CD31 (MEC 13.3, BD Biosciences) commands 20-30% price premium over human CD31 antibodies for IHC but enables consistent quantification across pre-clinical & clinical. MEC 13.3 sales grew 18% YoY (2025 vs. 2024), primarily from CROs supporting oncology drug development pipelines.
2. Segmentation: Monoclonal vs. Polyclonal
| Segment | 2025 Share | Key Advantages | Primary Applications | Average Price per 100 μg |
|---|---|---|---|---|
| Monoclonal | 78% | Single epitope consistency, batch-to-batch reproducibility, clone-specific (JC70A,MEC13.3,390) | Clinical IHC (MVD scoring), preclinical MVD, flow cytometry, drug development | 250−250−500 |
| Polyclonal | 22% | Higher signal for WB, broader species cross-reactivity (human, mouse, rat, zebrafish) | Western blot, IP (low-expressing tissues), zebrafish/tissue IF | 150−150−350 |
Monoclonal antibodies dominate (78% share) for IHC-based MVD quantification in clinical trials and preclinical studies (requires lot-to-lot consistency across multi-year studies). Clone JC70A (human CD31) is the most published reference for tumor angiogenesis quantification. Clone MEC13.3 (mouse CD31) is the standard for preclinical models. Polyclonal retain share in WB and zebrafish applications where species cross-reactivity is needed.
3. Application Analysis: Tumor Angiogenesis, Cardiovascular Research
Tumor Angiogenesis & Drug Development (MVD Quantification) (52% of 2025 demand): Largest segment. A Q4 2025 Phase II trial of anti-VEGF agent in colorectal cancer used anti-CD31 IHC (clone JC70A, automated stainer) to quantify MVD (microvessel density) at baseline & week 6. MVD reduction >35% correlated with PFS benefit (HR=0.48,p=0.009). Clinical requirement: validated for FFPE IHC (automated stainer:Ventana,Leica BOND), strong membrane staining (no cytoplasmic noise), lot-to-lot consistency (<15% CV MVD counts), and quantitative reproducibility across pathologists (ICC>0.85).
Tumor Immunology & Microenvironment (20% of demand): A January 2026 multiplex IHC study in melanoma used CD31 plus α-SMA to distinguish CD31+ pericyte-poor angiogenic vessels, correlating with CD8+ T-cell infiltration. Requirement: multiplex compatibility (IF/IHC), bright fluorophores for CD31+ vessels.
Cardiovascular & Regenerative Medicine (15% of demand): Myocardial infarction (neovascularization), wound healing, engineered tissue vascularization. Regenerative requirement: cross-reactivity with rat/porcine CD31.
4. Competitive Landscape & Technical Challenges
Key Suppliers: BosterBio,Bio-Rad,BD Biosciences (MEC 13.3, clone 390),Abcam,RayBiotech,GeneTex,BioLegend (clone 390),Bethyl Laboratories,SouthernBiotech,Elabscience,Merck (clone JC70A),Leica Biosystems (CD31-1A10),Beijing Solarbio,Wuhan Fine Biotech,R&D Systems,Thermo Fisher,Novus Biologicals.
Technical Challenges: Epitope sensitivity to fixation — CD31 extracellular domain epitope sensitive to formalin over-fixation (>48 hrs). Rapid fixation (<24 hrs) & retrieval (citrate,pH6.0, high temp 95-100°C). Non-specific staining — CD31 antibodies cross-react with megakaryocytes/platelets in tissue vasculature (intra-vessel staining). Pathologists trained to exclude vessel lumen from MVD counts. Human vs mouse cross-reactivity — most human CD31 clones (JC70A) do not cross-react with mouse, requiring separate MEC 13.3 for pre-clinical.
Recent Developments (2025–2026):
- BD Biosciences (Dec 2025) launched “CD31 (MEC 13.3) Ultra-LEAF” (low endotoxin) for in vivo antibody blocking studies
- Abcam (Jan 2026) introduced recombinant rabbit monoclonal CD31 (clone EPR17259) for enhanced FFPE IHC (human, cross-reacts with mouse)
- Leica Biosystems (Oct 2025) received CE-IVD certification for CD31-1A10 on BOND platform (automated IHC)
- International MVD working group (2026) updated consensus guidelines: recommend CD31 as preferred pan-endothelial marker (vs. CD34)
5. Forecast & Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $52M | $76M | 5.6% |
| Monoclonal share | 78% | 83% | - |
| Mouse-specific (MEC13.3) share | ~25% | ~35% | 7-8% |
| Clinical trial MVD IHC share | ~30% | ~40% | - |
| Asia-Pacific share | 18% | 28% | 7.0% |
- Fastest-growing region: Asia-Pacific (CAGR 7.0%), China (angiogenesis biotech,VEGF biosimilar development) and Japan/Korea
- Fastest-growing segment: Mouse-specific CD31 (MEC13.3) (CAGR 7-8%) for pre-clinical syngeneic models
- Price trends: Standard monoclonal stable/slight decline (-1-2% annual); specialized IHC kits stable (+2-3%)
Conclusion
Anti-CD31 antibodies remain the gold standard for endothelial cell detection and microvessel density quantification. Global Info Research recommends clinical trial sponsors (anti-angiogenic agents) select validated monoclonal CD31 (JC70A) IHC kits, automated stainer compatibility; pre-clinical oncology researchers require mouse-specific CD31 (MEC13.3); vascular biologists need dual human/mouse cross-reactive clones (EPR17259). As anti-angiogenic combination therapies expand, CD31 IHC remains essential.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
